Published in final edited form as:

Curr Hepatol Rep. 2015 June ; 14(2): 139–143. doi:10.1007/s11901-015-0265-7.

Treatment of Hepatic Adenomatosis

Claire Meyer, MD* and **Mauricio Lisker-Melman, MD****

*Dr. Claire Meyer, cmeyer@dom.wustl.edu, Fellow in Gastroenterology, Division of Gastroenterology, Washington University School of Medicine, South Euclid Ave, Box 8124, St. Louis, MO, 63110, Tel 314 454 8141

**Dr. Mauricio Lisker-Melman, mlisker@dom.wustl.edu, Professor of Medicine, Director Hepatology Program, Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave, Box 8124, St. Louis, MO, 63110, Tel 314 454 8141

Abstract

Hepatic adenomatosis and hepatocellular adenomas share risk factors and the same pathophysiologic spectrum. The presence in the liver of 10 hepatocellular adenomas defines hepatic adenomatosis. The diagnosis may be established incidentally during a liver radiologic examination in the asymptomatic patient, or after associated right upper quadrant pain, hepatomegaly or liver test abnormalities. Upon the diagnosis of hepatic adenomatosis or either of its life-threatening complications - hemorrhage and progression to hepatocellular carcinoma - consideration should be given to potential medical, radiologic and surgical interventions including: observation (estrogens and androgens withdrawal), resection, transarterial embolization, radiofrequency ablation and liver transplantation. The management of patients with hepatic adenomatosis can be challenging. These patients should be ideally referred to centers with expertise in the management of liver diseases.

Keywords

Hepatic adenomatosis; liver adenomatosis; treatment of hepatic adenomatosis; management of liver adenomatosis

Introduction

Balancing the real risk of life-threatening complications in hepatic adenomatosis – hemorrhage and progression to hepatocellular carcinoma – with the hazard of invasive interventions on numerous benign liver lesions presents a management challenge. Here we review the diagnosis and classification of hepatic adenomatosis and the therapeutic options for this unusual liver entity.

Correspondence to: Mauricio Lisker-Melman.

Conflict of Interest

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Background

Definition

Hepatic adenomatosis is characterized by multiple adenomas in an otherwise-normal liver (1). The minimum number of adenomas required to for a diagnosis of adenomatosis was originally arbitrarily defined as ten (1), and this remains the most widely-used definition, although in more recent years a minimum number of four to establish the diagnosis has been proposed (2). While hepatic adenomatosis has historically been regarded as an entity distinct from solitary hepatocellular adenomas, the two conditions are now thought to exist on the same pathophysiologic spectrum, with similar genetic alterations and clinical complications (3, 4).

Clinical history and presentation

Known risk factors for the development of hepatocellular adenomas include exogenous (or elevated levels of endogenous (5)) estrogen/progesterone (6) or androgens (7), glycogen storage diseases (8), maturity onset diabetes of the young type 3 (MODY3) (9), iron overload disorders (10), obesity and the metabolic syndrome (11, 12), and vascular abnormalities (13). In men, excessive alcohol and tobacco use are also recognized risk factors (14). Although patients with a history of glycogen storage disease or exogenous estrogen or androgen use were excluded from the original description of hepatic adenomatosis, given the subsequent findings of the same cellular and molecular processes as in cases with fewer adenomas, it is likely that risk factors are the same for both conditions, although perhaps to varying degrees.

Patients with hepatic adenomatosis may present with abdominal pain, hepatomegaly, and/or elevated liver enzymes – in this case, alkaline phosphatase and gamma-glutamyltransferase. In asymptomatic patients, the diagnosis is determined after the incidental finding of multiple adenomas on imaging (13). While hemorrhage within an adenoma may be asymptomatic, bleeding (either intra-tumoral or intra-peritoneal due to adenoma rupture) may be the initial presentation; it is characterized by abdominal pain, an acute increase in abdominal girth (in the case of intraperitoneal bleeding), decrease in hematocrit, and in some cases hemodynamic instability (15). Hemorrhage is the most common complication of hepatocellular adenomatosis, reported in 42-62.5% in case series (1, 2). The risk of progression to malignancy (hepatocellular carcinoma), on the other hand, is estimated to be less than 10% (16).

Diagnosis and classification

The diagnosis of hepatic adenomatosis may in some cases be made based on CT or MR imaging, or suspected based on ultrasound. If active bleeding is suspected, CT angiography can provide the most timely information for patients who may need urgent intervention (15). Otherwise, in the absence of contraindications, contrast-enhanced MR has the advantage of being able to distinguish between some subtypes of adenomas (17).

Based on imaging findings, hepatic adenomatosis can be further classified as massive (in which lesions enlarge and deform the contour of the liver) or multifocal (multiple smaller

lesions with a normal liver size and contour); the former is considered more difficult to manage surgically (18). Imaging findings relevant to whether resection may be indicated include size of the lesions, evidence of bleeding, and/or changes suggestive of malignant transformation. In addition, the location of the lesions and the amount of normal-appearing liver remaining informs whether resection is feasible (19).

Current guidelines from the American College of Gastroenterology recommend that “biopsy should be reserved for cases in which imaging is inconclusive and biopsy is deemed necessary to make treatment decisions” (5). Biopsy can distinguish between the four subtypes of hepatic adenomas: hepatocyte nuclear factor 1-alpha (HNF1A) inactivated, inflammatory, B-catenin activated, and unclassifiable (those lacking the characteristic findings of the other subtypes) (8), as shown in Table 1. Variations of inflammatory adenomas include those with activated B-catenin (20) and those with telangiectatic features (formerly termed telangiectatic focal nodular hyperplasia) (5). When molecular testing for mutations in the genes encoding HNF1A and B-catenin is not feasible, these subtypes may be identified based on immunohistochemistry showing absent liver fatty acid binding protein (L-FABP) in the case of inactivated HNF1A, or B-catenin accumulation in the nucleus and increased cytoplasmic glutamine synthase in the case of activated B-catenin (20, 21). Nuclear accumulation of B-catenin may also be seen due to mutation of the APC gene in hepatocellular adenomas in patients with familial adenomatous polyposis (FAP), and hepatic adenomatosis due to inactivated HNF1A has also been reported in an FAP patient (8). Notably, activated B-catenin may be present in some but not all adenomas in a given patient (21). Risk of progression to malignancy is lower in HNF1A-inactivated adenomas and higher in those with activated B-catenin, while telangiectatic adenomas have a high risk of bleeding (5, 8).

Management

General considerations

Once the diagnosis of hepatic adenomatosis is established, estrogens and androgens should be withdrawn or avoided given the increased risk of bleeding associated with their use (5, 16). In the absence of evidence of benefit from estrogen deprivation by oophorectomy or tamoxifen administration, these measures are typically not recommended (2). Guidelines suggest that “pregnancy is not generally contraindicated in cases of hepatocellular adenoma <5cm” (5). Regarding the safety of anticoagulation and/or antiplatelet agents in patients with hepatic adenomatosis, there is little to guide clinicians, though one case series of patients with spontaneous liver bleeding found rates of anticoagulant and antiplatelet use similar to that in the general population (15, 22). Finally, genetic counseling should be considered in patients with hepatic adenomatosis related to inactivated HNF1A, which is a germline mutation in some cases and can be associated with MODY3 (16).

Observational management

Asymptomatic patients with hepatic adenomatosis whose largest lesion is ≤ 3 cm, not increasing in size on serial imaging, and without high-risk features on biopsy or imaging (see “resection,” below) are considered at low risk of complications (bleeding or malignant

transformation) and appropriate for observational management with serial imaging and measurement of alpha fetoprotein (AFP) (2, 23).

Imaging (CT or MR, with intravenous contrast) and AFP should be performed at least yearly; ACG guidelines suggest surveillance every six months for two years following diagnosis and yearly thereafter (2, 5, 13). AFP alone is not sufficient as it may remain normal even in cases of malignancy (8). This observation strategy is also applicable to patients who have had a large adenoma resected but have smaller adenomas remaining elsewhere in the liver (2). Although 5 cm is often cited as the size criteria for more aggressive treatment, some have suggested resection of any lesions > 3 cm that are easily amenable to surgery (23); the most appropriate management of lesions between 3 and 5 cm is not well established (24) and should be individualized based on patient and tumor characteristics.

Resection

Resection can be considered in symptomatic patients, those with lesions 5 cm or larger (given higher risk of bleeding or malignant transformation), and those with lesions with a size increase of 1 cm or more on serial imaging (2, 5, 24). In addition to size, the presence of high risk features on imaging or biopsy should prompt the physician to consider resection. These features include: evidence of abnormal B-catenin, telangiectatic or unclassified subtypes, and hypervascularity (5, 8, 25). In addition, males with hepatic adenomatosis are at higher risk of complications, so resection of small lesions (<5 cm) could be considered in this population (8). The finding of dysplasia or atypia on biopsy of a hepatocellular adenoma should also prompt consideration of resection, as this does not regress with withdrawal of exogenous steroids, and may progress to malignancy even if the size of the lesion decreases on subsequent imaging (8). The finding of malignant transformation (hepatocellular carcinoma) on biopsy or imaging in the setting of hepatic adenomatosis requires aggressive management, as detailed elsewhere (26).

Transarterial embolization

For actively hemorrhaging lesions in hepatic adenomatosis, management similar to that recommended for bleeding liver tumors in general is likely applicable, given that hepatic adenomas constitute a substantial proportion of tumors in case series of bleeding (40% in one series, for example (22)), and recent evidence suggests that management considerations in cases of adenomatosis and solitary or few adenomas are similar (4). Transarterial embolization (TAE) is considered to be the first-line treatment for active bleeding and is successful in achieving hemostasis in more than 80% of cases; in cases where embolization cannot be performed, surgical hemostasis (packing for 24–72 hours) is an alternative (15). Poor outcomes from emergent liver resection make this a treatment choice of last resort, if at all, for persistent bleeding (4, 15). For actively hemorrhaging lesions successfully treated with embolization, elective liver resection can be considered after 3–6 months, when hematoma resorption allows for less-extensive resection with fewer complications (4, 15).

In non-bleeding adenomas, embolization is an option in cases where resection is indicated based on the criteria outlined above, but cannot be performed due to patient or tumor factors

(ie, comorbidities, difficult-to-resect locations) (5). In addition, TAE can be considered as a less invasive option in pregnant patients for whom resection would otherwise be indicated (27). In highly vascular tumors, pre-operative embolization may be performed in an effort to decrease surgical bleeding risk (25). In case series, embolization has most often been performed for patients with multiple lesions requiring treatment, likely due to the fact that resection of multiple tumors may not be feasible given the need to retain at least 20% of functioning liver (19, 25). Risks of TAE include treatment failure, post-embolization syndrome (fever and abnormal liver function tests), and the possibility of non-absorbable embolization materials making future hepatic surgeries more difficult (15).

Radiofrequency ablation

Radiofrequency ablation (RFA) for hepatocellular adenoma has been described, and like TAE may lead to a decrease in the size of lesions (27). In general, RFA and TAE can be considered in the same setting – ie, cases where resection is indicated but not feasible due to characteristics of the patient or the lesions. In one case series of 18 patients, 50% required more than one session of RFA (28).

Liver transplantation

Hepatocellular adenomatosis is a rare indication for liver transplantation; a 2005 review found 17 case reports in the literature (29), with at least six cases reported since then (4, 19, 24, 30–32). It can be considered as one of the treatment options for hepatocellular carcinoma in cases where adenomatosis progresses to malignancy. It has also been reported in cases of bleeding in hepatocellular adenomatosis too extensive to resect and in cases of significant tumor re-growth following resection (13, 19).

Conclusions

The management of hepatic adenomatosis – the presence of multiple adenomas in an otherwise-normal liver – is driven by the assessment of the risk of its primary complications: hemorrhage and progression to hepatocellular carcinoma. Risk assessment requires cross-sectional imaging to determine the size, vascularity, and subtype of lesions. In some cases, biopsy is needed to determine subtype and may also disclose the presence of atypia or dysplasia. Even in those cases deemed to be low risk, the risk of occult or evolving malignancy warrants close observation with CT or MR imaging and AFP measurement at least yearly. Resection is indicated for lesions 5 cm or larger, as well as symptomatic patients and those with lesions with high-risk features on imaging or biopsy. Transarterial embolization and radiofrequency ablation are options in cases where resection is indicated but not practicable due to patient comorbidities or the location of the lesion(s). Liver transplantation is an option in rare cases of significant complications from unresectable adenomas.

Acknowledgments

Claire Meyer reports NIH support under award number T32DK007130. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Mauricio Lisker-Melman is a member of the Speaker Bureau of Gilead, Abbvie and Simply Speaking.

References

Papers of particular interest, published recently, have been highlighted as:

* Of importance

** Of major importance

1. Flejou JF, Barge J, Menu Y, Degott C, Bismuth H, Potet F, et al. Liver adenomatosis. An entity distinct from liver adenoma? *Gastroenterology*. 1985 Nov; 89(5):1132–1138. PubMed PMID: 2412930. Epub 1985/11/01. eng. [PubMed: 2412930]
2. Ribeiro A, Burgart LJ, Nagorney DM, Gores GJ. Management of liver adenomatosis: results with a conservative surgical approach. *Liver Transpl Surg*. 1998 Sep; 4(5):388–398. PubMed PMID: 9724476. Epub 1998/09/02. eng. [PubMed: 9724476]
3. Frulio N, Chiche L, Bioulac-Sage P, Balabaud C. Hepatocellular adenomatosis: what should the term stand for! *Clin Res Hepatol Gastroenterol*. 2014 Apr; 38(2):132–136. PubMed PMID: 24126236. Epub 2013/10/16. eng. [PubMed: 24126236]
4. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. *Gastroenterology*. 2009 Nov; 137(5):1698–1705. PubMed PMID: 19664629. Epub 2009/08/12. eng. [PubMed: 19664629]
5. Marrero JA, Ahn J, Rajender Reddy K. ACG clinical guideline: the diagnosis and management of focal liver lesions. *Am J Gastroenterol*. 2014 Sep; 109(9):1328–1347. quiz 48. PubMed PMID: 25135008. Epub 2014/08/20. eng. [PubMed: 25135008] Provides up-to-date evidence-based management guidelines.
6. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. *Jama*. 1979 Aug 17; 242(7):644–648. PubMed PMID: 221698. Epub 1979/08/17. eng. [PubMed: 221698]
7. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. *Am J Hematol*. 2004 Nov; 77(3):257–267. PubMed PMID: 15495253. Epub 2004/10/21. eng. [PubMed: 15495253]
8. Liao SS, Qureshi MS, Praseedom R, Huguet E. Molecular pathogenesis of hepatic adenomas and its implications for surgical management. *J Gastrointest Surg*. 2013 Oct; 17(10):1869–1882. PubMed PMID: 23835731. PMCID: Pmc3782654. Epub 2013/07/10. eng. [PubMed: 23835731] Describes management implications of hepatic adenoma subtypes.
9. Reznik Y, Dao T, Coutant R, Chiche L, Jeannot E, Clauin S, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. *J Clin Endocrinol Metab*. 2004 Mar; 89(3):1476–1480. PubMed PMID: 15001650. Epub 2004/03/06. eng. [PubMed: 15001650]
10. Radhi JM, Loewy J. Hepatocellular adenomatosis associated with hereditary haemochromatosis. *Postgrad Med J*. 2000 Feb; 76(892):100–102. PubMed PMID: 10644389. PMCID: Pmc1741485. Epub 2000/01/22. eng. [PubMed: 10644389]
11. Bunchorntavakul C, Bahirwani R, Drazek D, Soulen MC, Siegelman ES, Furth EE, et al. Clinical features and natural history of hepatocellular adenomas: the impact of obesity. *Aliment Pharmacol Ther*. 2011 Sep; 34(6):664–674. PubMed PMID: 21762186. Epub 2011/07/19. eng. [PubMed: 21762186]
12. Bioulac-Sage P, Taouji S, Possenti L, Balabaud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. *Liver Int*. 2012 Sep; 32(8):1217–1221. PubMed PMID: 22429502. Epub 2012/03/21. eng. [PubMed: 22429502]
13. Grazioli L, Federle MP, Ichikawa T, Balzano E, Nalesnik M, Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. *Radiology*. 2000 Aug; 216(2):395–402. PubMed PMID: 10924560. Epub 2000/08/05. eng. [PubMed: 10924560]
14. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. *Hepatology*. 2009 Aug; 50(2):481–489. PubMed PMID: 19585623. Epub 2009/07/09. eng. [PubMed: 19585623]

15. Darnis B, Rode A, Mohkam K, Ducerf C, Mabrut JY. Management of bleeding liver tumors. *J Visc Surg.* 2014 Jun 17. PubMed PMID: 24950941. Epub 2014/06/22. Eng. Summarizes current evidence applicable to the management of hepatic adenomas complicated by hemorrhage.
16. Greaves WO, Bhattacharya B. Hepatic adenomatosis. *Arch Pathol Lab Med.* 2008 Dec; 132(12): 1951–1955. PubMed PMID: 19061298. Epub 2008/12/09. eng. [PubMed: 19061298]
17. Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. *Hepatology.* 2008 Sep; 48(3):808–818. PubMed PMID: 18688875. Epub 2008/08/09. eng. [PubMed: 18688875]
18. Chiche L, Dao T, Salame E, Galais MP, Bouvard N, Schmutz G, et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. *Ann Surg.* 2000 Jan; 231(1):74–81. PubMed PMID: 10636105. PMCID: Pmc1420968. Epub 2000/01/15. eng. [PubMed: 10636105]
19. Wellen JR, Anderson CD, Doyle M, Shenoy S, Nadler M, Turmelle Y, et al. The role of liver transplantation for hepatic adenomatosis in the pediatric population: case report and review of the literature. *Pediatr Transplant.* 2010 May; 14(3):E16–E19. PubMed PMID: 19490491. Epub 2009/06/06. eng. [PubMed: 19490491]
20. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. *Gastroenterology.* 2013 May; 144(5):888–902. PubMed PMID: 23485860. Epub 2013/03/15. eng. [PubMed: 23485860]
21. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. *Hepatology.* 2007 Sep; 46(3):740–748. PubMed PMID: 17663417. Epub 2007/08/01. eng. [PubMed: 17663417]
22. Battula N, Tsapralis D, Takhar A, Coldham C, Mayer D, Isaac J, et al. Aetio-pathogenesis and the management of spontaneous liver bleeding in the West: a 16-year single-centre experience. *HPB (Oxford).* 2012 Jun; 14(6):382–389. PubMed PMID: 22568414. PMCID: Pmc3384862. Epub 2012/05/10. eng. [PubMed: 22568414]
23. Deneve JL, Pawlik TM, Cunningham S, Clary B, Reddy S, Scoggins CR, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. *Ann Surg Oncol.* 2009 Mar; 16(3):640–648. PubMed PMID: 19130136. Epub 2009/01/09. eng. [PubMed: 19130136]
24. Ramia JM, Bernardo C, Valdivieso A, Dopazo C, Jover JM, Albiol MT, et al. [Multicentre study on hepatic adenomas]. *Cir Esp.* 2014 Feb; 92(2):120–125. PubMed PMID: 23827931. Epub 2013/07/06. Estudio multicentrico sobre adenomas hepaticos. spa. [PubMed: 23827931]
25. Karkar AM, Tang LH, Kashikar ND, Gonen M, Solomon SB, Dematteo RP, et al. Management of hepatocellular adenoma: comparison of resection, embolization and observation. *HPB (Oxford).* 2013 Mar; 15(3):235–243. PubMed PMID: 23374365. PMCID: Pmc3572286. Epub 2013/02/05. eng. [PubMed: 23374365]
26. Kulik LM, Chokeychachaisakul A. Evaluation and Management of Hepatocellular Carcinoma. *Clin Liver Dis.* 2015 Feb; 19(1):23–43. PubMed PMID: 25454295. Epub 2014/12/03. Eng. [PubMed: 25454295]
27. Huurman VA, Schaapherder AF. Management of ruptured hepatocellular adenoma. *Dig Surg.* 2010; 27(1):56–60. PubMed PMID: 20357452. Epub 2010/04/02. eng. [PubMed: 20357452]
28. van Vledder MG, van Aalten SM, Terkivatan T, de Man RA, Leertouwer T, Ijzermans JN. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. *J Vasc Interv Radiol.* 2011 Jun; 22(6):787–793. PubMed PMID: 21616431. Epub 2011/05/28. eng. [PubMed: 21616431]
29. Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. *HPB (Oxford).* 2005; 7(3): 186–196. PubMed PMID: 18333188. PMCID: Pmc2023950. Epub 2008/03/12. eng. [PubMed: 18333188]
30. Di Sandro S, Slim AO, Lauterio A, Giacomoni A, Mangoni I, Aseni P, et al. Liver adenomatosis: a rare indication for living donor liver transplantation. *Transplant Proc.* 2009 May; 41(4):1375–1377. PubMed PMID: 19460563. Epub 2009/05/23. eng. [PubMed: 19460563]

31. Cimsit B, Schilsky M, Moini M, Cartiera K, Arvelakis A, Kulkarni S, et al. Combined liver kidney transplantation: critical analysis of a single-center experience. *Transplant Proc.* 2011 Apr; 43(3): 901–904. PubMed PMID: 21486624. Epub 2011/04/14. eng. [PubMed: 21486624]
32. Fernandez-Vega I, Santos-Juanes J, Garcia-Pravia C, Fresno-Forcelledo MF, Rodrigo L. Hepatic adenomatosis: A rare cause of liver transplant. *Rev Esp Enferm Dig.* 2014 Aug; 106(7):494–496. PubMed PMID: 25490174. Epub 2014/12/10. Hepatic adenomatosis: A rare cause of liver transplant. Eng. [PubMed: 25490174]
33. Nault JC, Zucman Rossi J. Molecular classification of hepatocellular adenomas. *Int J Hepatol.* 2013; 2013:315947. PubMed PMID: 23401783. PMCID: Pmc3562579. Epub 2013/02/13. eng. [PubMed: 23401783]

Table 1

References: (20, 33)

HEPATIC ADENOMAS					
Adenoma type	% of all adenomas	Mutation	Clinical Association	Radiology	Histochemistry
Hepatocyte Nuclear Factor 1 alpha	30–40%	HNF1A gene	Familial adenomatosis Intense steatosis Maturity-onset diabetes of the young type 3	Diffuse signal dropout on T1 weighted sequence	Loss of liver fatty acid binding protein
Beta Catenin Activated	10–15%	Beta catenin gene	Males High-risk of malignancy Mutation also present in subset of inflammatory adenomas	No specific radiologic characteristics	Glutamine synthase positive Nuclear beta catenin positive
Inflammatory	40–50%	Genes IL6ST/gp130 GNAS STAT3 ----- Unknown mutation	Inflammatory syndrome with anemia Castleman Disease McCune-Albright Syndrome	Intense signal on T2 weighted sequence and enhancement in Portal venous phase	Cytoplasmic overexpression of Serum amyloid A and C-reactive protein
Unclassified	10%	Undetermined	Oral contraception as described for other adenomas	No specific radiologic characteristics	-----